

REQUEST FOR PROPOSAL: FINANCING INTEGRATED DISEASE ELIMINATION IN ASIA PACIFC

COMPANY PROFILE

The Asia Pacific Leaders Malaria Alliance ("APLMA") unites 22 governments in Asia-Pacific who have committed to eliminating malaria in the region by 2030. APLMA translates evidence to advocate for policy change at the highest levels of government and supports leadership collaboration across the region. By convening senior officials beyond health, evidence monitoring and reporting on progress and bottlenecks and facilitating cross-border collaboration, APLMA supports and provides governments and political leaders access to regional and national insights, as well as visibility on the game-changing approaches and tools they need to end malaria.

For more information, please go to: https://www.aplma.org

BACKGROUND

APLMA has worked over the past decade to build commitment for a malaria-free Asia Pacific among the highest levels of leaders in the region. APLMA occupies a unique role among organizations based in the region as an advocate for malaria, as well as a broker and convener, able to engage at the highest levels of the political, diplomatic, and private spheres, working with leaders and decision-makers beyond traditional health actors. In particular, APLMA works intimately with National Malaria Programmes (NMPs) and partner institutions, who implement diverse strategies to combat malaria and accelerate progress towards elimination.

One such strategy is to integrate malaria control efforts with public health programmes for other diseases. Following WHO's Global Vector Control Response 2017 – 2030, many countries have worked to integrate malaria with other vector-borne diseases (VBDs), neglected tropical diseases (NTD), as well as integrated community case management (iCCM). Some countries also jointly manage malaria efforts with HIV/AIDS, Tuberculosis (TB) and/or other non-communicable diseases (NCDs). APLMA has recently published a case study of existing disease integration efforts in Asia Pacific on some of such existing efforts.

Disease integration offers numerous benefits including efficient resource utilisation, strengthened health systems, improved surveillance and data management, better health outcomes, and sustainable programmes in the long term. Being highly cost-effective, disease integration has the potential to narrow the malaria funding gap in Asia Pacific – which stands at an estimated US\$271M post-2026¹, when several Asian countries will no longer qualify for external donor support.

CALL FOR PROPOSAL

APLMA is seeking a consulting firm or organisation to:

¹ Analysis of Global Fund Funding Requests 2023 – 2025



- 1. Articulate trade-offs that NMPs make when faced with funding gaps
- 2. Identify potential integration/joint disease elimination opportunities for malaria financing Asia Pacific
- 3. Seek initial feedback from key stakeholders, relevant experts, and funders

The scope of work is expected to be completed before the end of April 2024 (negotiable).

SCOPE OF WORK

- Articulate Trade-offs: Examine successful financing mechanisms of disease integration
 programmes which include malaria that have been implemented in Asia Pacific. It should
 interview NMPs and relevant stakeholders of three identified countries to understand and
 where possible quantify the impact of trade-offs that are made when faced with funding
 gaps. Additionally, it should quantify the cost savings that integrated programmes can
 make, as opposed to running separate programmes in parallel.
- Identify Integration Opportunities: Identify new potential opportunities for integration between NMPs and other initiatives (these can range from other vector-borne diseases such as dengue and lymphatic filariasis, other neglected tropical diseases (NTDs), targeted public health programmes such as maternal and child health, to health topics such as nutrition).
- 3. **Propose Funding Structures:** Conduct in-depth discussions with 2 3 potential funders and propose 1 2 financing structures to fund integrated disease elimination in Asia Pacific. It should consider the establishment of regional funds through blended financing or other structures that can pool funding from diverse funders. This could be for groups of countries such as within the Melanesia sub-region or for selected high-burden or near-elimination countries. It should also identify possible host organisations to manage the funds and outline implementation mechanisms for the request and disbursement of funding to recipient countries.
- 4. **Seek Feedback:** Organise and facilitate a roundtable session to gather feedback from key stakeholders, relevant experts, and potential funders on the discussion paper and the proposed 1 2 financing structure(s).

DELIVERABLES

- Create short case study documents for three identified countries facing funding shortfalls.
 These will detail the aspects of NMPs that will not be delivered (i.e. trade-offs) in these
 countries and demonstrate (and where possible quantify) the likely impact on the affected
 populations.
- A discussion paper on the potential integration/joint disease elimination opportunities for malaria financing, as well as an accompanying PowerPoint deck which makes the case for 1 – 2 specific structures that can finance integrated disease elimination in Asia Pacific.



REQUIREMENTS

- Demonstrated experience in scoping, developing and launching financing mechanisms for global health. Prior experience in disease areas that have seen integration with malaria control/elimination efforts within Asia Pacific would be advantageous.
- Existing senior-level relationships with multilateral development banks, development financial institutions and grant-making organisations globally and in Asia Pacific. Preference for firms/organisations based in Asia Pacific.

To apply, please send your proposal to admin@aplma.org by 9 January 2024 with "Financing Integrated Disease Elimination" in the subject of the email. If applying as an organisation, please send a credentials document highlighting relevant past projects, cover letter, and an itemized quotation. We thank you for your interest and regret that only shortlisted candidates will be contacted.

APLMA is an equal-opportunity employer. All qualified applicants will receive consideration for employment regardless of race, colour, religion, gender, gender identity or expression, sexual orientation, genetics, disability or age.